Abstract

BackgroundLess than 50 patients with FPD/AML (OMIM 601309) have been reported as of today and there may an underestimation. The purpose of this study was to describe the natural history, the haematological features and the genotype-phenotype correlations of this entity in order to, first, screen it better and earlier, before leukaemia occurrence and secondly to optimize appropriate monitoring and treatment, in particular when familial stem cell transplantation is considered.MethodsWe have investigated 41 carriers of RUNX1 alteration belonging to nine unrelated French families with FPD/AML and two syndromic patients, registered in the French network on rare platelet disorders from 2005 to 2015.ResultsFive missense, one non-sense, three frameshift mutations and two large deletions involving several genes including RUNX1 were evidenced. The history of familial leukaemia was suggestive of FPD/AML in seven pedigrees, whereas an autosomal dominant pattern of lifelong thrombocytopenia was the clinical presentation of two. Additional syndromic features characterized two large sporadic deletions. Bleeding tendency was mild and thrombocytopenia moderate (>50 x109/L), with normal platelet volume. A functional platelet defect consistent with a δ-granule release defect was found in ten patients regardless of the type of RUNX1 alteration. The incidence of haematological malignancies was higher when the mutated RUNX1 allele was likely to cause a dominant negative effect (19/34) in comparison with loss of function alleles (3/9). A normal platelet count does not rule out the diagnosis of FPD/AML, since the platelet count was found normal for three mutated subjects, a feature that has a direct impact in the search for a related donor in case of allogeneic haematopoietic stem cell transplantation.ConclusionsPlatelet dysfunction suggestive of defective δ-granule release could be of values for the diagnosis of FPD/AML particularly when the clinical presentation is an autosomal dominant thrombocytopenia with normal platelet size in the absence of familial malignancies. The genotype-phenotype correlations might be helpful in genetic counselling and appropriate optimal therapeutic management.

Highlights

  • Less than 50 patients with FPD/acute myeloid leukaemia (AML) (OMIM 601309) have been reported as of today and there may an underestimation

  • Platelet dysfunction suggestive of defective δ-granule release could be of values for the diagnosis of FPD/AML when the clinical presentation is an autosomal dominant thrombocytopenia with normal platelet size in the absence of familial malignancies

  • The genotype-phenotype correlations might be helpful in genetic counselling and appropriate optimal therapeutic management

Read more

Summary

Introduction

Less than 50 patients with FPD/AML (OMIM 601309) have been reported as of today and there may an underestimation. The involved genes are RUNX1 (familial platelet disorder with propensity to develop acute myeloid leukaemia, FPD/AML, OMIM 601399) [1], CEBPA [2] and more recently GATA-2 [3] and ETV6 [4]. The clinical usefulness of identifying these syndromes, which may be more common than previously thought, is obvious They raise questions about their clinical detection and management. Heterozygous germline nonsense or missense mutations in RUNX1 were identified as the causative abnormality in FPD/AML, the first described of the four [1]. Time elapsed between the detection of thrombocytopenia and the diagnosis of FPD/AML can amount to several years: FPD/AML diagnosis remains a challenge This is of utmost importance when an intra-familiar donor is considered for hematopoietic stem cell transplantation (HSCT) [10]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.